Molecular Breast Cancer Imaging in the Era of Precision Medicine

Muzahir, Saima

doi:10.2214/ajr.20.22883

Cited by 14 publications

(10 citation statements)

References 90 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Alternatively, PET/MRI systems are increasingly being utilized for evaluation of disease extent or treatment response in breast cancer [ 66 , 93 ]. Breast-specific PET imaging using positron emission mammography (PEM) or dedicated breast PET systems (dbPET) have also been proposed for breast cancer imaging [ 72 , 94 , 95 , 96 , 97 ]. These typically offer improved PET resolution compared with whole-body PET cameras, may allow imaging in the prone position similar to breast MRI, and allow PET guidance for tissue biopsy [ 66 , 97 ].…”

Section: Breast Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Covington

Koppula

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

Positron emission tomography combined with x-ray computed tomography (PET-CT) is an advanced imaging modality with oncologic applications that include staging, therapy assessment, restaging, and surveillance. This six-part series of review articles provides practical information to providers and imaging professionals regarding the best use of PET-CT for the more common adult malignancies. The second article of this series addresses primary thoracic malignancy and breast cancer. For primary thoracic malignancy, the focus will be on lung cancer, malignant pleural mesothelioma, thymoma, and thymic carcinoma, with an emphasis on the use of FDG PET-CT. For breast cancer, the various histologic subtypes will be addressed, and will include 18F fluorodeoxyglucose (FDG), recently Food and Drug Administration (FDA)-approved 18F-fluoroestradiol (FES), and 18F sodium fluoride (NaF). The pitfalls and nuances of PET-CT in breast and primary thoracic malignancies and the imaging features that distinguish between subcategories of these tumors are addressed. This review will serve as a resource for the appropriate roles and limitations of PET-CT in the clinical management of patients with breast and primary thoracic malignancies for healthcare professionals caring for adult patients with these cancers. It also serves as a practical guide for imaging providers, including radiologists, nuclear medicine physicians, and their trainees.

show abstract

Section: Breast Cancermentioning

confidence: 99%

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Covington

Koppula

Fine

et al. 2022

Cancers

View full text Add to dashboard Cite

show abstract

“…The incremental cancer detection rate per 1,000 exams in individuals with dense breasts is approximately 1.7 for tomosynthesis, 2.7 for ultrasound, 15 for full-protocol MRI, and 10 for abbreviated MRI (15). MBI also provides favorable false-positive rates (20), favorable recall rates (8), rapid interpretation times (18), low cost (15), few contraindications (21), and a high negative predictive value (22). Disadvantages of MBI for supplemental screening include an imaging exam time of 28-40 min (15), the need for nuclear medicine licensing and coordination between nuclear medicine and breast imaging sections, lack of widespread availability, variable insurance coverage, and a higher whole-body radiation exposure than for other supplemental screening options (10,13,15).…”

Section: Indications and Clinical Applications Supplemental Screeningmentioning

confidence: 99%

“…When used for supplemental screening, the estimated benefit of MBI in terms of deaths averted is 5-9 times greater than the estimated risk of lives lost (23), and the estimated benefit-to-radiation risk ratio now approaches that of mammography (23). However, concerns regarding MBI radiation risks, though disputed, have delayed widespread use for supplemental screening (10,21,23). The American College of Radiology appropriateness criteria for supplemental breast cancer screening based on breast density currently do not recommend MBI (24).…”

Section: Indications and Clinical Applications Supplemental Screeningmentioning

confidence: 99%

Advances and Future Directions in Molecular Breast Imaging

et al. 2021

View full text Add to dashboard Cite

Molecular breast imaging (MBI) using 99m Tc-sestamibi has advanced rapidly over the past decade. Technical advances allow lower-dose, higher-resolution imaging and biopsy capability. MBI can be used for supplemental breast cancer screening with mammography for women with dense breasts, as well as to assess neoadjuvant therapy response, evaluate disease extent, and predict breast cancer risk. This article highlights the current state of the art and future directions in MBI.

show abstract

“…Breast cancer became the number one killer of women . Estrogen receptor (ER)-positive takes up the highest ratio (∼70%–80%) in breast malignancies . Hence, it is highly crucial and necessary for an ER accurate diagnosis, which guides hormone therapy planning and prognosis .…”

mentioning

confidence: 99%

“…1 Estrogen receptor (ER)-positive takes up the highest ratio (∼70%−80%) in breast malignancies. 2 Hence, it is highly crucial and necessary for an ER accurate diagnosis, which guides hormone therapy planning and prognosis. 3 Tumors with a high expression of ERs are usually administered with an antiestrogen hormone therapy and tend to have a good prognosis.…”

mentioning

confidence: 99%

Radioiodinated Ethinylestradiol Derivatives for Estrogen Receptor Targeting Breast Cancer Imaging

Liu

Lin

et al. 2022

ACS Med. Chem. Lett.

View full text Add to dashboard Cite

Two novel PEGylated ethinylestradiol (PEG = poly(ethylene glycol)) estrogen receptor (ER) targeting probes [131I]EITE and [131I]MITE were synthesized and evaluated. Both probes had a nanomolar binding affinity to the ER receptor (36.47 nM for [131I]EITE and 61.83 nM for [131I]MITE). They showed high uptake in ER-positive MCF-7 cells and tumors, which could be significantly blocked by a coinjection of excess estradiol. Their ER specificities were further demonstrated by the low uptake in ER-negative MDA-MB-231 cells and tumors. The maximum tumor-to-muscle (T/M) ratios reach to 6.59 for [131I]EITE at 1 h postinjection (p.i.) and to 3.69 for [131I]MITE at 2 h p.i. in MCF-7 tumors. Among these two probes, [131I]EITE showed a faster tumor accumulation and a higher T/M ratio indicating it could be a better candidate for the potential diagnosis of ER-positive breast cancers.

show abstract

Molecular Breast Cancer Imaging in the Era of Precision Medicine

Cited by 14 publications

References 90 publications

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

PET-CT in Clinical Adult Oncology: II. Primary Thoracic and Breast Malignancies

Advances and Future Directions in Molecular Breast Imaging

Radioiodinated Ethinylestradiol Derivatives for Estrogen Receptor Targeting Breast Cancer Imaging

Contact Info

Product

Resources

About